Literature DB >> 34469242

Evaluation of a New Viral Vaccine Vector in Mice and Rhesus Macaques: J Paramyxovirus Expressing Hemagglutinin of Influenza A Virus H5N1.

Mathew Abraham1, Ashley C Beavis1, Peng Xiao2, Francois J Villinger2, Zhuo Li1, Cheryl A Jones1, S Mark Tompkins1, Biao He1.   

Abstract

H5N1, an avian influenza virus, is known to circulate in many Asian countries, such as Bangladesh, China, Cambodia, Indonesia, and Vietnam. The current FDA-approved H5N1 vaccine has a moderate level of efficacy. A safe and effective vaccine is needed to prevent outbreaks of highly pathogenic avian influenza (HPAI) H5N1 in humans. Nonsegmented negative-sense single-stranded viruses (NNSVs) are widely used as a vector to develop vaccines for humans, animals, and poultry. NNSVs stably express foreign genes without integrating with the host genome. J paramyxovirus (JPV) is a nonsegmented negative-strand RNA virus and a member of the proposed genus Jeilongvirus in the family Paramyxoviridae. JPV-specific antibodies have been detected in rodents, bats, humans, and pigs, but the virus is not associated with disease in any species other than mice. JPV replicates in the respiratory tract of mice and efficiently expresses the virus-vectored foreign genes in tissue culture cells. In this work, we explored JPV as a vector for developing an H5N1 vaccine using intranasal delivery. We incorporated hemagglutinin (HA) of H5N1 into the JPV genome by replacing the small hydrophobic (SH) gene to generate a recombinant JPV expressing HA (rJPV-ΔSH-H5). A single intranasal administration of rJPV-ΔSH-H5 protected mice from a lethal HPAI H5N1 challenge. Intranasal vaccination of rJPV-ΔSH-H5 in rhesus macaques elicited antigen-specific humoral and cell-mediated immune responses. This work demonstrates that JPV is a promising vaccine vector. IMPORTANCE A highly pathogenic avian influenza (HPAI) H5N1 outbreak in Southeast Asia destroyed millions of birds. Transmission of H5N1 into humans resulted in deaths in many countries. In this work, we developed a novel H5N1 vaccine candidate using J paramyxovirus (JPV) as a vector and demonstrated that JPV is an efficacious vaccine vector in animals. Nonsegmented negative-sense single-stranded viruses (NNSVs) stably express foreign genes without integrating into the host genome. JPV, an NNSV, replicates efficiently in the respiratory tract and induces robust immune responses.

Entities:  

Keywords:  H5N1; J paramyxovirus; vaccine

Mesh:

Substances:

Year:  2021        PMID: 34469242      PMCID: PMC8549524          DOI: 10.1128/JVI.01321-21

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

Authors:  John J Treanor; James D Campbell; Kenneth M Zangwill; Thomas Rowe; Mark Wolff
Journal:  N Engl J Med       Date:  2006-03-30       Impact factor: 91.245

2.  The L gene of J paramyxovirus plays a critical role in viral pathogenesis.

Authors:  Zhuo Li; Jie Xu; Zhenhai Chen; Xiudan Gao; Lin-Fa Wang; Christopher Basler; Kaori Sakamoto; Biao He
Journal:  J Virol       Date:  2013-09-25       Impact factor: 5.103

Review 3.  H5N1 influenza viruses: outbreaks and biological properties.

Authors:  Gabriele Neumann; Hualan Chen; George F Gao; Yuelong Shu; Yoshihiro Kawaoka
Journal:  Cell Res       Date:  2009-11-03       Impact factor: 25.617

Review 4.  The current state of H5N1 vaccines and the use of the ferret model for influenza therapeutic and prophylactic development.

Authors:  David Banner; Alyson A Kelvin
Journal:  J Infect Dev Ctries       Date:  2012-06-15       Impact factor: 0.968

5.  Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004.

Authors:  Elena A Govorkova; Jerold E Rehg; Scott Krauss; Hui-Ling Yen; Yi Guan; Malik Peiris; Tien D Nguyen; Thi H Hanh; Pilipan Puthavathana; Hoang T Long; Chantanee Buranathai; Wilina Lim; Robert G Webster; Erich Hoffmann
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

6.  Human infection with a novel avian-origin influenza A (H7N9) virus.

Authors:  Rongbao Gao; Bin Cao; Yunwen Hu; Zijian Feng; Dayan Wang; Wanfu Hu; Jian Chen; Zhijun Jie; Haibo Qiu; Ke Xu; Xuewei Xu; Hongzhou Lu; Wenfei Zhu; Zhancheng Gao; Nijuan Xiang; Yinzhong Shen; Zebao He; Yong Gu; Zhiyong Zhang; Yi Yang; Xiang Zhao; Lei Zhou; Xiaodan Li; Shumei Zou; Ye Zhang; Xiyan Li; Lei Yang; Junfeng Guo; Jie Dong; Qun Li; Libo Dong; Yun Zhu; Tian Bai; Shiwen Wang; Pei Hao; Weizhong Yang; Yanping Zhang; Jun Han; Hongjie Yu; Dexin Li; George F Gao; Guizhen Wu; Yu Wang; Zhenghong Yuan; Yuelong Shu
Journal:  N Engl J Med       Date:  2013-04-11       Impact factor: 91.245

Review 7.  Emergence and pandemic potential of swine-origin H1N1 influenza virus.

Authors:  Gabriele Neumann; Takeshi Noda; Yoshihiro Kawaoka
Journal:  Nature       Date:  2009-06-18       Impact factor: 49.962

Review 8.  Highly pathogenic avian influenza (H5N1): pathways of exposure at the animal-human interface, a systematic review.

Authors:  Maria D Van Kerkhove; Elizabeth Mumford; Anthony W Mounts; Joseph Bresee; Sowath Ly; Carolyn B Bridges; Joachim Otte
Journal:  PLoS One       Date:  2011-01-24       Impact factor: 3.240

9.  Efficacy of a parainfluenza virus 5 (PIV5)-based H7N9 vaccine in mice and guinea pigs: antibody titer towards HA was not a good indicator for protection.

Authors:  Zhuo Li; Jon D Gabbard; Scott Johnson; Daniel Dlugolenski; Shannon Phan; S Mark Tompkins; Biao He
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

Review 10.  Clinical Advances in Viral-Vectored Influenza Vaccines.

Authors:  Sarah Sebastian; Teresa Lambe
Journal:  Vaccines (Basel)       Date:  2018-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.